Ostin Technology Group Co., Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OST research report →
Price Chart
About the company
Ostin Technology Group Co. , Ltd. , a company based in China, specializes in the creation and production of sophisticated thin-film transistor liquid crystal display (TFT-LCD) modules, along with essential polarizers.
- CEO
- Tao Ling
- IPO
- 2022
- Employees
- 131
- HQ
- Nanjing, JS, CN
Get TickerSpark's AI analysis on OST
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.11M
- P/E
- -0.77
- PEG
- -0.00
- P/S
- 0.28
- P/B
- 4.01
- EV/EBITDA
- -5.93
- Div Yield
- 0.00%
- Gross Margin
- 5.76%
- Op Margin
- -22.37%
- Net Margin
- -26.39%
- ROE
- -201.42%
- ROIC
- -21.05%
Latest fiscal year · YoY change
- Revenue
- $39.68M+22.2%
- Gross Profit
- $2.54M+50.6%
- Op Income
- $-9,076,623
- Net Income
- $-10,015,732+0.5%
- EPS
- $-4.38+97.4%
- OCF Growth
- +101.7%
- FCF Growth
- +3.3%
- 52W High
- $235.00
- 52W Low
- $1.35
- 50D MA
- $2.24
- 200D MA
- $55.79
- Beta
- 0.57
- RSI (14)
- 100
- Avg Volume
- 742.52K
No earnings-call transcripts are available for OST yet.
- Free Float
- 82.2%
- Shares Outstanding
- 5.96M
- Float Shares
- 4.90M
of shares held by institutions
8 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Citadel Advisors LLC | 34.65K | 0 |
| Morgan Stanley | 2.63K | 0 |
| Banque Cantonale Vaudoise | 2.09K | 0 |
| Federation Des Caisses Desjardins Du Quebec | 403 | 0 |
| Groupe La Francaise | 334 | ▲ 334 |
| Wells Fargo & Company/Mn | 160 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | CUI RONGGUO | other | 0 |
| Mar 18, 26 | Yin Xiao Hong | other | 0 |
| Mar 18, 26 | Mein John Carl | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OST coverage
Recent articles, reports, and earnings notes.
No research on OST yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OST report →OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
newsfilecorp.com · Nov 10
OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial
newsfilecorp.com · Nov 5
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
newsfilecorp.com · Oct 6
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
newsfilecorp.com · Sep 24
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
newsfilecorp.com · Sep 17
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
newsfilecorp.com · Sep 8
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
newsfilecorp.com · Sep 2
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
newsfilecorp.com · Aug 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.